Precision’s Allo CAR-T Inches Closer To Filling Post-Auto CAR-T Niche

 
• By Alaric DeArment

The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.

Precision BioSciences announced Phase I/IIa data for its allogeneic CAR-T therapy • Source: Shutterstock

More from Immuno-oncology

More from Anticancer